Sparsentan Improves Glomerular Hemodynamics, Cell Functions and Tissue Repair in a Mouse Model of FSGS
Cardiovascular, Kidney Failure, and All-Cause Mortality Events in Patients with Focal Segmental Glomerulosclerosis in a U.S. Real-World Database
The Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of Immunoglobulin A Nephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS) on Patients and Care-Partners Study (HONUS): Results for IgAN and FSGS in Europe
Sparsentan Has Direct Effects on the Glomerular Capillary Wall to Attentuate Increased Permeability After Exposure to Nephrotic Syndrome Plasma
Natural History of Idiopathic Nephrotic Syndrome: The UK National RaDaR Idiopathic Nephrotic Syndrome Cohort
American Society of Nephrology (ASN) Kidney Week 2024
October 23 - 27, 2024
CA
Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety
European Renal Association (ERA) Congress 2024
May 23 - 26, 2024
Stockholm
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study
FILSPARI (sparsentan): Changes in Blood Pressure and Hypotensive Events in FSGS
FILSPARI (sparsentan): Effect on Estimated Glomerular Filtration Rate (eGFR) in FSGS
FILSPARI (sparsentan): Dosing and Administration in Clinical Trials of FSGS
Physiologically-Based Pharmacokinetic Model of Sparsentan to Evaluate Drug-Drug Interaction Potential